<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625023</url>
  </required_header>
  <id_info>
    <org_study_id>IFOM-CPO007/2019/PO006</org_study_id>
    <nct_id>NCT04625023</nct_id>
  </id_info>
  <brief_title>A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer</brief_title>
  <acronym>METAMECH</acronym>
  <official_title>A Master Protocol Empowering Mechanobiology Translation Research in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IFOM, The FIRC Institute of Molecular Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IFOM, The FIRC Institute of Molecular Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      METAMECH is a master observational protocol designed to empower a bi-directional&#xD;
      collaboration between basic and clinical research, an essential prerequisite to feed and&#xD;
      implement precision oncology.&#xD;
&#xD;
      METAMECH will follow a stage-mixed cohort of at least 500 patients through their course of&#xD;
      treatments, until death or a minimum of 5 years. Patients will be longitudinally sampled and&#xD;
      matched clinical data (including imaging) will be collected. Via a multi-tiered informed&#xD;
      consensus process, METAMECH will also allow to develop companion diagnostics for molecular&#xD;
      enrichment strategies in AIRC-driven proof-of-concept trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METAMECH has been designed to streamline the study of the co-evolutionary landscape between&#xD;
      tumor and host cells in a cohort of breast cancer (BC) patients, with the aim of&#xD;
      understanding how their outcomes can be significantly improved (e.g. reduction of their&#xD;
      chance of recurrence and survival improve). This clinical resource for integrative clinical&#xD;
      data and sample collection will allow to generate hypotheses on mechanisms supporting the&#xD;
      outgrowth of human metastases, mine for new potentially actionable targets and the selection&#xD;
      of appropriate patients for experimentally-driven trials. To achieve the required level of&#xD;
      'experimental precision', patients will enter METAMECH at two different 'therapeutic&#xD;
      checkpoints': i) prior to a tumor sampling event (surgery, biopsy) or ii) prior to any line&#xD;
      of treatment.&#xD;
&#xD;
      To optimize the enrollment of patients, the longitudinal collection of data/samples and their&#xD;
      logistic management, METAMECH has been designed as a flexible infrastructure organized in&#xD;
      Tiers for the stepwise comprehension of the biological processes that drive tumor evolution,&#xD;
      and precisely:&#xD;
&#xD;
        -  TIER0, Retrieving: the ability to retrospectively retrieve clinically annotated BC&#xD;
           archival samples to validate/discover new mechanotransduction-linked biomarkers;&#xD;
&#xD;
        -  TIER1, Recording: the ability to prospectively record BC characteristics under standard&#xD;
           of care treatments and to define new mechanotransduction-linked biomarkers;&#xD;
&#xD;
        -  TIER2, Modelling: the ability to develop pertinent experimental models to study the&#xD;
           aberrant mechanisms underlying the metastatic outgrowth and define&#xD;
           mechanotransduction-targeting therapeutic strategies;&#xD;
&#xD;
        -  TIER3, Linking: the ability to access data and samples of patients enrolled in POC&#xD;
           trials to prove the efficacy and study/understand resistance mechanisms of&#xD;
           mechanotransduction-targeting therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients recruited in TIER0 and TIER 1</measure>
    <time_frame>6 months</time_frame>
    <description>Number of recruited BC cases in TIER 0 and in TIER 1 with complete clinically annotated FFPE and/or frozen biological samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients recruited in TIER2</measure>
    <time_frame>6 months</time_frame>
    <description>Number of recruited BC cases in TIER 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients triaged in proof-of concept (POC) clinical trials</measure>
    <time_frame>6 months</time_frame>
    <description>Number of BC cases recruited in TIER 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>New prognostic mechanotransduction-linked markers</measure>
    <time_frame>6 months</time_frame>
    <description>Number of identified/validated new prognostic mechanotransduction-linked markers</description>
  </other_outcome>
  <other_outcome>
    <measure>New predictive mechanotransduction-linked markers</measure>
    <time_frame>6 months</time_frame>
    <description>Number of identified/validated new predictive mechanotransduction-linked markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers correlation with RR</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between identified biomarkers with therapies response rates (RR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers correlation with PFS</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between identified biomarkers with progression-free survival (PFS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers correlation with OS</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between identified biomarkers with overall survival (OS)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort of BC patients</arm_group_label>
    <description>Stage-mixed cohort of at least 500 breast cancer patients through their course of treatment, until death or a minimum of 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Retrospective cohorts and Prospective observation of standard clinical practice</description>
    <arm_group_label>Cohort of BC patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  FFPE tissue&#xD;
&#xD;
        -  Fresh Tissue (tumor and normal)&#xD;
&#xD;
        -  Plasma&#xD;
&#xD;
        -  PBMC&#xD;
&#xD;
        -  Whole Blood&#xD;
&#xD;
        -  Stools&#xD;
&#xD;
        -  Buccal Swabs&#xD;
&#xD;
        -  Pleural effusions and ascites&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stage-mixed Breast Cancer (BC) patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Verification that the patient could not be reached for informed consent in accordance&#xD;
             with applicable national regulations or, alternatively, TIER1 written Informed&#xD;
             consent.&#xD;
&#xD;
          2. Patients ≥18 years of age.&#xD;
&#xD;
          3. Previous diagnosis of breast cancer, or a strong suspicion of BC based on clinical and&#xD;
             radiological findings.&#xD;
&#xD;
          4. ECOG Performance status &lt; 2 (only for TIER1-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other current malignancy or malignancy diagnosed or relapsed within the past 5&#xD;
             years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ&#xD;
             cervical cancer)&#xD;
&#xD;
          2. Patient unable to comply with the study protocol owing to psychological, social or&#xD;
             geographical reasons.&#xD;
&#xD;
          3. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus&#xD;
             (HCV) or syphilis infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Marsoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IFOM- FIRC Institute of Molecular Biology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Lazzari, PhD</last_name>
    <phone>+3902574303799</phone>
    <email>clinical.trials@ifom.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florida Voli, PhD</last_name>
    <phone>+3902574303236</phone>
    <email>clinical.trials@ifom.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asst Papa Giovanni Xxiii</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Zambelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Vernieri, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS, Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Maggiore della Carità di Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS (IOV)</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PierFranco Conte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS, Policlinico San Matteo Pavia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Pedrazzoli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena di Roma - Istituti Fisioterapici Ospitalieri (IFO)</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Blandino, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

